IGC is developing a laboratory survey tool to determine whether laboratory facilities in Pakistan have the capacity to detect Candida auris, a newly emerging fungal infection that is spreading rapidly worldwide. We will be piloting surveillance in three initial hospital sites in Islamabad. Integral is working with the CDC to develop SOPs for laboratory diagnosis, surveillance, and reporting. This is a new and unique project that has not been done before and will help shed light on laboratory practices, burden of disease in hospitals, and build capacity to better detect the pathogen. To learn more about C. auris, click here – or check out the New York Times article here.